Cefepime therapy for cefepime- susceptible extended-spectrum β-lactamase-producing enterobacteriaceae bacteremia

Ruibin Wang, Sara E. Cosgrove, Sarah Tschudin-Sutter, Jennifer H. Han, Alison E. Turnbull, Alice J. Hsu, Edina Avdic, Karen C. Carroll, Pranita D. Tamma

Research output: Contribution to journalArticlepeer-review

Abstract

The role of cefepime for extended-spectrum β-lactamase (ESBL) bacteremia is unclear if susceptible in vitro. In a propensity score-matched study of patients with ESBL bacteremia, risk of death was 2.87 times higher for patients receiving cefepime compared with carbapenems (95% confidence interval [CI],.88-9.41). We compared 14-day mortality of patients with ESBL bacteremia receiving empiric cefepime versus empiric carbapenem therapy in a propensity score-matched cohort. There was a trend towards increased mortality in the cefepime group (hazard ratio, 2.87; 95% CI,.88-9.41), which enhances the existing literature suggesting that cefepime may be suboptimal for invasive ESBL infections.

Original languageEnglish (US)
JournalOpen Forum Infectious Diseases
Volume3
Issue number3
DOIs
StatePublished - May 1 2016

Keywords

  • Bacteremia
  • Carbapenem
  • Cefepime
  • ESBL
  • Multidrug-resistant organisms

ASJC Scopus subject areas

  • Oncology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Cefepime therapy for cefepime- susceptible extended-spectrum β-lactamase-producing enterobacteriaceae bacteremia'. Together they form a unique fingerprint.

Cite this